Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
9
×
life sciences
national blog main
san francisco blog main
9
×
clinical trials
national top stories
new york blog main
new york top stories
san francisco top stories
fda
deals
national
san diego blog main
san diego top stories
startups
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
cancer
cancer drugs
eli lilly
investing
nonalcoholic steatohepatitis
president trump
acute myeloid leukemia
What
biotech
9
×
research
medicines
new
roundup
days
drug
annual
attention
bio
cancer
companies
control
drugs
ipo
news
startup
therapeutics
today
week
abbvie
according
ahead
aiming
aims
akcea
alliance
alzheimer’s
ambien
ambys
american
approach
arrival
asco
assessed
attendees
august
based
big
black
Language
unset
Current search:
biotech
×
" boston top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More